No connection

Search Results

GENB vs TNDM

GENB
Generate Biomedicines, Inc.
BEARISH
Price
$11.53
Market Cap
$1.47B
Sector
Healthcare
AI Confidence
85%
TNDM
Tandem Diabetes Care, Inc.
BEARISH
Price
$21.24
Market Cap
$1.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GENB
--
TNDM
--
Forward P/E
GENB
-5.44
TNDM
-899.24
P/B Ratio
GENB
-0.94
TNDM
9.35
P/S Ratio
GENB
46.08
TNDM
1.43
EV/EBITDA
GENB
--
TNDM
-26.6

Profitability

Gross Margin
GENB
0.0%
TNDM
53.81%
Operating Margin
GENB
-737.04%
TNDM
2.86%
Profit Margin
GENB
0.0%
TNDM
-20.17%
ROE
GENB
-81.72%
TNDM
-97.89%
ROA
GENB
-34.63%
TNDM
-5.28%

Growth

Revenue Growth
GENB
--
TNDM
2.7%
Earnings Growth
GENB
--
TNDM
--

Financial Health

Debt/Equity
GENB
--
TNDM
2.9
Current Ratio
GENB
2.85
TNDM
2.55
Quick Ratio
GENB
2.69
TNDM
1.89

Dividends

Dividend Yield
GENB
--
TNDM
--
Payout Ratio
GENB
0.0%
TNDM
0.0%

AI Verdict

GENB BEARISH

GENB presents a high-risk speculative profile with a Piotroski F-Score of 4/9, indicating only marginal financial stability. The company exhibits severe fundamental distress, characterized by a negative Price-to-Book ratio (-0.94) and an extreme Price-to-Sales ratio of 46.08, suggesting the market is pricing in immense future growth that is not yet supported by revenue. While the current ratio of 2.85 provides a short-term liquidity cushion, the operating margin of -737.04% and a 0/100 technical trend signal strong downward momentum. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual deterministic financial health and price action.

Strengths
Strong short-term liquidity with a Current Ratio of 2.85
Healthy Quick Ratio of 2.69 indicating low reliance on inventory
Strong analyst backing with a target price of $25.00
Risks
Extreme valuation with a Price/Sales ratio of 46.08
Negative equity as evidenced by the Price/Book ratio of -0.94
Severe operational losses with an operating margin of -737.04%
TNDM BEARISH

TNDM exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While analysts maintain a 'buy' rating with a target of $30.62, the company suffers from negative profit margins (-20.17%), a deeply negative ROE (-97.89%), and high leverage (Debt/Equity of 2.90). Despite a strong current ratio providing short-term liquidity, the lack of meaningful revenue growth (2.70%) and bearish insider sentiment suggest the current price is speculative rather than fundamentally supported.

Strengths
Strong short-term liquidity (Current Ratio 2.55, Quick Ratio 1.89)
Healthy Gross Margin of 53.81%
Significant analyst support with a mean target price of $30.62
Risks
Critical financial health (Piotroski F-Score 1/9)
High leverage with a Debt/Equity ratio of 2.90
Stagnant revenue growth (2.70% YoY) relative to sector expectations

Compare Another Pair

GENB vs TNDM: Head-to-Head Comparison

This page compares Generate Biomedicines, Inc. (GENB) and Tandem Diabetes Care, Inc. (TNDM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile